The Hart-Scott-Rodino waiting period for the Barr’s acquisition of Shire’s Adderall expired without further action from the US Federal Trade Commission. As a result, the product acquisition agreement that Duramed Pharmaceuticals, a subsidiary of Barr, and Shire entered into can be finalized.
Under the terms of the agreement, Duramed will pay $63 million to purchase Shire’s Adderall tablets. The company will re-launch the product in December 2006.
Aderall is used as part of a total treatment program in children with behavioral disorders.